Revista Médica del Instituto Mexicano del Seguro Social

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2016, Issue S3

Carrillo-Gaucín S, Torres-Gómez LG
Carbetocin and oxytocin: Prevention of postpartum hemorrhage in patients with risk factors for uterine atony
Rev Med Inst Mex Seguro Soc 2016; 54 (S3)

Language: Español
References: 20
Page: 284-290
PDF: 285.73 Kb.

Full text


Background: In Mexico, during 2010, obstetric hemorrhage was second (19.6%) as a direct cause of maternal death. The aim of this paper is to evaluate the effect of oxytocin and carbetocin, in preventing postpartum hemorrhage in patients with risk factors for uterine atony.
Methods: Study type clinical trial, patients experiencing at least one of the risk factors for uterine atony included. Randomly, they were divided into two groups: one was given Oxytocin and other received Carbetocin. The following variables were determined: risk factors for uterine atony, hemoglobin and hematocrit, vital signs, trans-surgical bleeding, whether or not presented uterine atony, uresis, need for additional tonics uterus and need for blood transfusion.
Results: A total of 120 patients were studied in 6 months were excluded 3, 60 were treated with Carbetocin, and 57 with Oxytocin. It was determined that there is a greater number of events of uterine atony (p = 0.007, with RR 11.06) and therefore greater need for additional tonic uterus (p = 0.027, with RR 5.44) in the group of Oxytocin. There was no statistically significant difference in the other variables.
Conclusions: Carbetocin is recommended as prophylaxis of obstetric hemorrhage in patients with risk factors for uterine atony.

Key words: Prevention and control, Postpartum Hemorrhage, Uterus.


  1. Secretaría de Salud. Lineamiento técnico: Prevención, Diagnóstico y Manejo de la Hemorragia Obstétrica: Centro Nacional de Equidad de Género y Salud Reproductiva. México; 2009.

  2. Secretaría de Salud. Programa Nacional de Salud 2007-2012. Por un México sano: construyendo alianzas para una mejor salud. México: Secretaría de Salud; 2007. Disponible en http://www.conadic.salud. gob.mx/pdfs/programas/pns_version_completa.pdf

  3. World Health Organization. Trends in maternal mortality: 1990 to 2008. Switzerland: World Health Organization; 2010. Disponible en http://whqlibdoc. who.int/publications/2010/9789241500265_eng.pdf

  4. Haeri S, Dildy GA. Maternal mortality from hemorrhage. Semin Perinatol. 2012;36(1):48-55.

  5. Ruiz-Rosas RA. Hemorragia obstétrica, causa de muerte materna. IMSS, 2011. Rev Med Inst Mex Seguro Soc 2012;50(6):659-664.

  6. Secretaría de Salud. Guía de Práctica Clínica. Diagnóstico y Tratamiento de la Hemorragia Obstétrica en la Segunda Mitad del Embarazo y Puerperio Inmediato, México: Secretaria de Salud; 2009.

  7. Al JF. Grandmultiparity: a potential risk factor for adverse pregnancy outcomes. J Reprod Med. 2012;57 (1-2):53-57.

  8. Protocolos Asistenciales en Obstetricia, Fármacos uteroestimulantes, Sociedad Española de Ginecología y Obstetricia, España; 2012.

  9. Boucher M, Horbay GL, Griffin P, Deschamps Y, Desjardins C, Schulz M, et al. Double-blind randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing caesarean section. J Perinatol. 1998;18(3):202-207.

  10. Sweeney G, Holbrook AM, Levine M, Yip M, Alfredson K, Cappi S, et al. Pharmacokinetics of carbetocin, a long acting oxytocin analogue, in nonpregnant women. Curr Ther Res. 1990;47:528-540.

  11. Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani B et al. Carbetocin versus oxytocin in caesarean section with high risk of post-partum haemorrhage. Journal of Prenatal Medicine. 2013;7(1):12-18.

  12. Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, et al. Trends in postpartum hemorrhage in high resource countries: A review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;27:9-55.

  13. Cotter AM, Ness A, Tolosa JE. Prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev. 2001;4:CD001808.

  14. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2007;3:CD005457.

  15. Leduc D, Senikas V, Lalonde AB. Clinical Practice Obstetrics Committee; Society of Obstetricians and Gynaecologists of Canada. Active management of the third stage of labour: Prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2009;31:980-983.

  16. Angulo-Vázquez J, Cortés-Sanabria L, Torres-Gómez LG, Aguayo-Alcaraz G, Hernández-Higareda S, Ávalos-Nuño J. Análisis de la mortalidad materna, en tres periodos, en el HGO del CMNO. Ginecol Obstet Mex. 2007;75(7):384-93.

  17. Wetta LA, Szychowski JM, Seals S, Mancuso M, Biggio J, Tita A. Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery. Am J Obstet Gynecol. 2013;209(1):51.e1-6.

  18. Holleboom CAG, van Eyck J, Koenen SV. Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands. Arch Gynecol Obstet. 2013;287:1111–1117.

  19. Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol. 1999;180(3 Pt. 1):670-676.

  20. Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet. 2009;280:707-712.

>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2016, Issue S3

· Journal Index 
· Links 

Copyright 2019